HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield reiterates a Buy rating on Aldeyra Therapeutics (NASDAQ:ALDX) and maintains a $10 price target.
August 02, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Matthew Caufield reiterates a Buy rating on Aldeyra Therapeutics and maintains a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100